Altered neuroendocrine control of GH secretion in normal women of advanced reproductive age.
BACKGROUND
Previous studies have suggested that the neuroendocrine control of growth hormone (GH) secretion changes with increasing age in women with normal menstrual cycles and sex steroid levels.


METHODS
In order to verify this hypothesis, 8 younger (22-32 years) and 8 older (41-45 years) women with normal menstrual function and gonadal steroid levels were tested with the serotonergic agent sumatriptan (6 mg in a subcutaneous bolus), the GABAergic agonist sodium valproate (800 mg orally), the dopaminergic compound L-Dopa (500 mg orally) and placebos. Furthermore, all women were tested with GH-releasing hormone (GH-RH 1 microgram/kg body weight in an intravenous (i.v.) bolus) to determine whether GH secretion in response to its specific releasing factor was preserved. Serum GH levels were recorded over 2 hours in all tests and IGF-I levels in basal samples.


RESULTS
Plasma IGF-I concentrations and the GH responses to sumatriptan, sodium valproate and L-Dopa were significantly lower in older than in younger women. Also, the GH-RH-induced GH response was significantly lower in older than in younger subjects. When peak GH responses to releasing stimuli were compared with age, significant negative correlations were found in all tests.


CONCLUSIONS
These data did not show a specific neurotransmitter change underlying defective GH secretion in older aged reproductive women. On the other hand, the results indicated that age-related changes in the secretory machinery of GH, such as a reduced pituitary sensitivity to GH-RH and/or a reduction in the pituitary GH secretory capacity, affect women during the last years of the reproductive period.
Coiro
V
V
Department of Internal Medicine, University of Parma, Italy.
Volpi
R
R
Gramellini
D
D
Cigarini
C
C
Necchi Ghiri
S
S
Capretti
L
L
Caffarri
G
G
Chiodera
P
P
D000328:Adult; D000375:Aging / Q000097:blood / Q000502:physiology*; D018491:Dopamine Agonists / Q000494:pharmacology; D005260:Female; D018755:GABA Agonists / Q000494:pharmacology; D013007:Growth Hormone-Releasing Hormone / Q000494:pharmacology; D019382:Human Growth Hormone / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D007980:Levodopa / Q000494:pharmacology; D008875:Middle Aged; D009490:Neurosecretory Systems / Q000502:physiology*; D012016:Reference Values; D012098:Reproduction; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D018170:Sumatriptan / Q000494:pharmacology; D014635:Valproic Acid / Q000494:pharmacology
D018491:Dopamine Agonists; D018755:GABA Agonists; D017366:Serotonin Receptor Agonists; D019382:Human Growth Hormone; D007980:Levodopa; D014635:Valproic Acid; D007334:Insulin-Like Growth Factor I; D018170:Sumatriptan; D013007:Growth Hormone-Releasing Hormone